Ajanta Pharma Financial Statements

Ajanta Pharma (AJANTPHARM) reported revenue of ₹56.25B in FY2026 with net income of ₹10.56B. Total assets stood at ₹61.55B and free cash flow was ₹1.64B.

Ajanta Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		47.43B	56.25B
Cost of Rev. Cost of Revenue		-10.71B	-11.84B
Gross Profit		36.72B	44.41B
SGA Sales, General & Admin		-23.18B	-28.74B
Op. Income Operating Income		12.10B	13.94B
PBT Profit Before Tax		11.89B	13.78B
Net Income		9.20B	10.56B
Dil. Shares Diluted Shares		125.17M	124.95M
Diluted EPS		73.53	84.51

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Ajanta Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Ajanta Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		28.43B	37.35B
Non-curr. assets Total non-current assets		21.72B	24.19B
Total assets		50.15B	61.55B
Curr. liabilities Total current liabilities		9.96B	14.16B
Non-curr. liab. Total non-current liabilities		2.29B	2.12B
Total liabilities		12.25B	16.28B
Total equity		37.90B	45.27B
Total liab. & eq. Total liabilities & equity		50.15B	61.55B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Ajanta Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Ajanta Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		11.89B	13.78B
Operating CF Cash flow Operating Activities		11.57B	5.29B
Capex Investments in PPE		-3.18B	-3.65B
Investing CF Cash flow Investing Activities		-3.77B	-4.29B
Dividend Paid		-3.49B	-3.50B
Financing CF Cash flow Financing Activities		-7.33B	-1.68B
Cash (start) Cash at beginning of period		1.29B	1.75B
Cash (end) Cash at end of period		1.77B	1.07B
FCF Free Cash Flow		8.39B	1.64B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Ajanta Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026